Rhodin, Kristen E.
Jung, Sin-Ho
Elleson, Kelly
DePalo, Danielle
Straker, Richard
McKinley, Sophia
Beekman, Kate
Parker, Lily
Chen, Suephy
Iyer, Matthew K.
Salama, April K. S.
Bartlett, Edmund
Karakousis, Giorgos
Zager, Jonathan S.
Tyler, Douglas S.
Beasley, Georgia M.
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (1R38AI140297)
Article History
Received: 14 April 2023
Accepted: 23 June 2023
First Online: 22 July 2023
Disclosure
: K. Rhodin is supported by NIH 1R38AI140297. G. Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate. G. Beasley has been a one-time member of the advisory board for Cardinal Health and Regeneron. G. Beasley is supported by NIH K08 CA237726-01A1. A. Salama discloses Research Funding (paid to institution): Ascentage, BMS, Ideaya, Immunocore, Merck, Olatec Therapeutics, Pfizer, Regeneron Pharmaceuticals, Replimune, and Seattle Genetics; Advisory Boards: BMS, Iovance Biotherapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, and Replimune. E. Bartlett discloses institutional research funding from Skyline Dx and honorarium from Excite International. G. Karakousis discloses institutional research support from and advisory board work for Merck. J. Zager has done advisory board work for Merck.